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Abstract
Background: Consistent with its effect on gastric emptying, exenatide, an injectable treatment for type 2 diabetes,
may slow the absorption rate of concomitantly administered oral drugs resulting in a decrease in maximum
concentration (Cmax). This study evaluated the drug interaction potential of exenatide when administered
adjunctively with oral contraceptives, given their potential concomitant use.
Methods: This trial evaluated the effect of exenatide co-administration on single- and multiple-dose
pharmacokinetics of a combination oral contraceptive (ethinyl estradiol [EE] 30 μg, levonorgestrel [LV] 150 μg
[Microgynon 30®]). Thirty-two healthy female subjects participated in an open-label, randomised, crossover trial
with 3 treatment periods (oral contraceptive alone, 1 hour before exenatide, 30 minutes after exenatide). Subjects
received a single dose of oral contraceptive on Day 8 of each period and QD doses on Days 10 through 28.
During treatment periods of concomitant usage, exenatide was administered subcutaneously prior to morning and
evening meals at 5 μg BID from Days 1 through 4 and at 10 μg BID from Days 5 through 22. Single- (Day 8) and
multiple-dose (Day 22) pharmacokinetic profiles were assessed for each treatment period.
Results: Exenatide did not alter the bioavailability nor decrease daily trough concentrations for either oral
contraceptive component. No substantive changes in oral contraceptive pharmacokinetics occurred when oral
contraceptive was administered 1 hour before exenatide. Single-dose oral contraceptive administration 30 minutes
after exenatide resulted in mean (90% CI) Cmax reductions of 46% (42-51%) and 41% (35-47%) for EE and LV,
respectively. Repeated daily oral contraceptive administration 30 minutes after exenatide resulted in Cmax
reductions of 45% (40-50%) and 27% (21-33%) for EE and LV, respectively. Peak oral contraceptive concentrations
were delayed approximately 3 to 4 hours. Mild-to-moderate nausea and vomiting were the most common adverse
events observed during the trial.
Conclusions: The observed reduction in Cmax is likely of limited importance given the unaltered oral contraceptive
bioavailability and trough concentrations; however, for oral medications that are dependent on threshold
concentrations for efficacy, such as contraceptives and antibiotics, patients should be advised to take those drugs
at least 1 hour before exenatide injection.
Trial registration: ClinicalTrials.gov: NCT00254800.
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Background
Exenatide, a 39-amino acid peptide and antidiabetic agent
known as a glucagon-like peptide-1 receptor agonist, has
multiple glucoregulatory actions which are similar to
those of endogenous glucagon-like peptide-1. In the
European Union, it is an adjunctive therapy for patients
with type 2 diabetes who are suboptimally controlled with
metformin, a sulphonylurea, a thiazolidinedione, and com-
binations of metformin plus a sulphonylurea or metformin
plus a thiazolidinedione. In the United States, exenatide is
indicated as an adjunct to diet and exercise to improve
glycaemic control in adults with type 2 diabetes mellitus.
Following a subcutaneous dose (5 or 10 μg BID), exenatide
is rapidly absorbed with a time to peak concentration
(Tmax) of approximately 2 hours, has a terminal half-life
(t1/2) of 2.4 hours [1], and is predominantly eliminated by
passive renal mechanisms [2]. Exenatide has been shown
to reduce fasting and postprandial glucose by the com-
bined contribution of glucose-dependent insulin secretion,
suppression of glucagon secretion, and slowing of gastric
emptying [3-5]. There is evidence that this treatment also
reduces appetite [6] and energy intake [7].
Consistent with its pharmacological effect of slowing
gastric emptying, exenatide may reduce the rate of absorp-
tion of concomitantly administered oral drugs. Drug-drug
interaction studies with digoxin [8], warfarin [9], lovastatin
[10], and lisinopril [11] have demonstrated that concomi-
tant exenatide treatment reduced the maximum plasma
concentrations (Cmax) and delayed the Tmax for these
drugs, both of which are consistent with slowing of gastric
emptying. Reductions in overall exposure (area under the
curve [AUC]) were only observed in the exenatide-lovasta-
tin interaction study. However, given the known pharma-
cokinetic characteristics of exenatide, the potential for a
CYP3A induction was considered unlikely and the
observed results were considered to be related to incom-
plete characterization of the single-dose lovastatin AUC
following exenatide dosing. Acetaminophen [12], a marker
of gastric emptying, was studied with exenatide to under-
stand how the relative timing of exenatide administration
might change the magnitude of pharmacokinetic effects
observed for orally administered drugs. In addition, this
prior study provided information on the optimal timing
for administration of other concomitant oral medications.
Changes in the acetaminophen profile were not evident
when acetaminophen was given 1 hour prior to the exena-
tide dose as the absorption process for acetaminophen had
likely been completed before the onset of exenatide action.
However, a reduced Cmax and delayed Tmax were observed
when acetaminophen was given after exenatide adminis-
tration; the magnitude of changes was greatest 1 to 2
hours after exenatide administration.
The present study evaluated the drug-drug interaction
potential of exenatide with a widely used concomitantly
administered combination oral contraceptive (OC) con-
sisting of ethinyl estradiol (EE) and levonorgestrel (LV).
The study included a treatment period in which OC was
administered 30 minutes after exenatide, such that the
anticipated time of peak exposure of the oral contracep-
tive would coincide with the maximum effect of slowed
gastric emptying. A second treatment period with OC
administered 1 hour before exenatide was also included.
No interaction would be expected during the second
treatment period, as OC absorption was likely to be
completed prior to the onset of exenatide action. The
interaction was assessed after single, as well as multiple
doses of OC to maximise pharmacokinetic information
generated from the study.
Methods
Subjects
This study was conducted at 1 clinical study center in the
United Kingdom. The protocol was approved by the Inde-
pendent Ethics Committee Plymouth, UK, and was con-
ducted in accordance with the 1975 Declaration of
Helsinki, as revised in 2000 [13], and the European Com-
mission’s directive on clinical research (2001/20/CE) [14].
Before enrollment, all subjects provided written informed
consent. Subjects were required to be taking an OC prior
to study entry and be healthy pre-menopausal females, 18
to 45 years old, with a BMI between 19 to 35 kg/m2. Sub-
jects were excluded from the study if they had diabetes
mellitus or had received implanted contraceptives for 6
months or injectable contraceptives for 12 months prior
to the study. Grapefruit was restricted within 7 days and
concomitant drug therapies that could induce or inhibit
CYP3A were not permitted within 14 days before the first
drug administration. In case of mild intercurrent illness
during the study, ibuprofen and/or anti-emetic medica-
tions that would not affect gastrointestinal motility were
allowed at the discretion of the investigator. Lifestyle
habits of eligible subjects, such as smoking, alcohol con-
sumption, diet, and exercise, were not altered during the
study.
Study design
This was an open-label, 3-period, 3-sequence, randomised
crossover study in healthy female subjects who were using
OCs prior to study entry (clinicaltrials.gov registration:
NCT00254800). The primary objective was to evaluate the
effect of exenatide on the multiple-dose PK of a combina-
tion oral contraceptive (EE and LV) administered 1 hour
before and 30 minutes after the exenatide dose. Up to 40
subjects were to be enrolled to ensure that approximately
18 subjects completed the study. Comparing OC alone
and OC administered 1 hour before exenatide, a sample
size of 18 subjects was estimated to provide approximately
90% power to demonstrate that the 90% CI of the ratio of
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geometric means for AUC (EE or LV) would be contained
within the interval (0.80, 1.25). This sample size estimate
was based on an intra-subject coefficient of variation of
15%.
The OC combination product (Microgynon 30®) con-
sisted of EE, 30 μg and LV, 150 μg. Prior to starting the
active dosing period, screening was conducted over 2
visits. The purpose of the first screening visit, approxi-
mately 2 months prior to admission, was to initiate a
run-in period either to convert to the study OC or to
synchronise the OC cycle within a cohort of subjects.
The second screening visit occurred approximately 21
days prior to the first day of dosing to confirm study
eligibility.
Each subject participated in 3 treatment periods, each of
28 days duration: OC alone, OC 1 hour before exenatide,
and OC approximately 30 minutes after exenatide. Exena-
tide was self-administered 15 minutes prior to the morn-
ing and evening meals at 5 μg BID on Days 1 through
4 and increased to 10 μg BID on Days 5 through 22. Sub-
jects received a single dose of OC on Day 8 of each treat-
ment period; dosing was omitted on Day 9 to allow for
single-dose PK sampling. Subsequently, once-daily doses
of OC were resumed on Days 10 through 28. Given that
exenatide was administered 15 minutes before meals, OC
was administered either 75 minutes before the meal (ie,
1 hour before exenatide) or 15 minutes after the meal (ie,
30 minutes after exenatide), depending on the treatment
period. In the OC alone arm, all multiple OC doses and
the majority of the single OC doses were given approxi-
mately 75 minutes before the meal.
During each treatment period after the first dose of the
OC (Day 8), venous blood samples (4 mL each) were
taken pre-dose, and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6,
8, 10, 12, 16, 24 and 48 hours post-dose. Blood samples
were also taken following multiple doses of the OC (Day
22) pre-dose, and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8,
10, 12, 16 and 24 hours post-dose. At a minimum, subjects
were admitted to the Clinical Research Unit (CRU) on Day
7, resident on Day 8, and discharged on Day 9, then
admitted again on Day 21, resident on Day 22, and dis-
charged on Day 23. Subjects were required to attend the
CRU on Days 10 and 28 as outpatients. At the investiga-
tor’s discretion, subjects could be resident in the CRU or
attend as outpatients after the first exenatide dose (Day 1)
and upon dose increases to 10 μg (Day 5).
Bioanalytical methods
Human plasma PK samples obtained during this study
were analysed at PPD, Richmond, VA, USA. The samples
were analysed for EE and LV using validated liquid chro-
matography with tandem mass spectrometric methods
[15]. The lower limit of quantification was 2.00 pg/mL
for EE and 50.0 pg/mL for LV; the upper limit of
quantification was 200 pg/mL for EE and 12500 pg/mL
for LV and. The intra-assay accuracy (% relative error)
during partial validation ranged from -4.24% to 0.992%
for LV and from 0.233% to 2.96% for EE. The intra-assay
precision (% relative standard deviation) during partial
validation ranged from 6.30% to 8.67% for LV and from
4.63% to 12.1% for EE.
Pharmacokinetic assessments
Plasma EE and LV pharmacokinetics were characterised
by noncompartmental methods of analysis using WinNon-
Lin Professional Version 5.0.1 (Pharsight, Cary, NC).
Plasma concentrations for each OC component were
plotted semi-logarithmically against time following single
(Day 8) or multiple doses (Day 22). The maximum con-
centration after single or multiple doses (Cmax or Cmax, ss)
and the corresponding time of maximum concentration
(Tmax or Tmax, ss) were identified from the observed data.
After a single dose, the area under the concentration-time
curve up to the last sampling time point (AUC0-t, last) was
calculated and extrapolated to infinity (AUC0-∞) using the
log-linear trapezoidal rule. Following multiple-dose
administration of the OC, the area under the curve over
the 24-hour post-dose interval (AUC0-τ, ss) was calculated
on Day 22. Additionally, concentrations were tabulated at
the 24-hour post-dose scheduled time points following
single and multiple doses. These 24-hour post-dose con-
centrations are referred to as daily trough concentrations
in the remainder of the document.
Statistical methods
The statistical analysis included all data from subjects
who received at least 1 dose of drug, and who had evalu-
able PK data. The primary PK parameters analysed statis-
tically for EE and LV were AUC0-∞ and Cmax following
single-dose administration (Day 8) and AUC0-τ, ss and
Cmax, ss following multiple-dose administration (Day 22).
In addition, OC trough concentrations on Day 8 and Day
22 were analysed. PK parameters were log-transformed
(base e) prior to analysis. Single- (Day 8) and multiple-
dose (Day 22) PK profiles of EE and LV were assessed
separately. A linear mixed-effects model was applied that
included subject as a random effect, and treatment, per-
iod, and sequence as fixed effects. The differences
between treatments and the control (OC alone) were
back-transformed to yield the ratio of the LS geometric
mean for each PK parameter relative to the control treat-
ment, and the corresponding 90% CI. An interaction was
concluded when the 90% CI for the ratio of the LS geo-
metric mean was not contained within the pre-specified
interval (0.80, 1.25). Inter-and intra-subject variability
estimates were derived from the mixed-effects model.
Tmax was analysed separately for Day 8 and Day 22 using
the nonparametric Wilcoxon rank sum test.
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Safety assessments
Safety was assessed by recording spontaneously reported
adverse events and was evaluated at scheduled intervals
by physical examination, vital sign measurement (includ-
ing sitting blood pressure and heart rate), body weight
assessments, clinical laboratory tests (including serum




A total of 38 healthy female subjects entered the study,
32 of these subjects were randomly assigned to 1 of the
3 sequences. Of the 38 subjects who entered the study,
20 completed the 3 treatment periods, and 18 subjects
were withdrawn from the study. The mean (SD) age,
weight and body mass index (BMI) for the 32 subjects
assigned to treatment were 28 (6.8) years, 69.0 (9.3) kg
and 25.1 (3.2) kg/m2, respectively. The majority (n = 31)
of subjects were Caucasian. Twelve subjects were
smokers.
Six subjects were withdrawn during the lead-in period,
prior to being randomly assigned to a sequence. Four of
these 6 subjects withdrew their consent during the run-
in period because they were unable to participate on the
required study dates. One subject was withdrawn due to
appendicitis. One subject was withdrawn due to proto-
col non-compliance. The other 12 subjects were with-
drawn after being assigned to treatment: 10 subjects due
to adverse events and 2 subjects due to withdrawal of
consent. Two of the 12 subjects were withdrawn when
OC was given alone, 5 when OC was given 1 hour
before exenatide, and 5 when OC was given 30 minutes
after exenatide.
Safety and tolerability
No break-through bleeding was reported during the
study. The incidence of adverse events considered to be
related to OC was generally similar across all treat-
ments. An increase in the incidence of adverse events
overall was observed with concomitant administration of
exenatide and OC compared to administration of OC
alone. The majority of subjects experienced adverse
events considered to be related to exenatide. Overall,
nausea and vomiting were reported by 91% and 81% of
subjects, respectively. All cases of nausea were mild or
moderate in severity. One case of vomiting was consid-
ered to be severe. Twenty subjects received concomitant
medication for the treatment and/or prophylaxis of nau-
sea and vomiting, and 6 subjects were withdrawn from
the study due to mild or moderate nausea or vomiting.
The incidence of vomiting was higher when the OC was
administered 30 minutes after exenatide (74%), com-
pared to 58% when administered 1 hour before
exenatide; however, these incidences were not statisti-
cally different.
Seventeen subjects (53%) in the study reported skin-
related adverse events, including injection-site rash (11
subjects) and skin rash (8 subjects). The skin-related
adverse events were considered by the investigator to be
related to exenatide in all but one of the cases. Two
subjects were withdrawn from the study due to rash.
There were no clinically important trends in the
serum biochemistry, hematology, urinalysis, blood pres-
sure, heart rate, or 12-lead electrocardiogram data from
baseline in each treatment period to follow-up.
Pharmacokinetics
For subjects who discontinued the study prior to com-
pletion of all 3 treatment periods, pharmacokinetics
(PK) data generated in other completed periods were
included in the PK assessments. Although some subjects
experienced vomiting on PK-assessment days, none of
these data were excluded from analyses as their concen-
trations at a scheduled time point were within the pre-
specified outlier threshold of 3 standard deviations from
the mean for the remainder of concentrations at that
time point.
Single-dose pharmacokinetics
Mean plasma concentration time profiles following single-
dose administration EE and LV are shown in Figures 1
(EE) and 2 (LV). Mean plasma concentration time profiles
associated with OC given 1 hour before exenatide were
similar to those observed with OC alone. Mean plasma EE
and plasma LV concentration time profiles following OC
administration 30 minutes after exenatide were charac-
terised by a reduced Cmax and delayed Tmax.
Statistical comparisons for single-dose PK parameters
are shown in Table 1 (EE) and Table 2 (LV). Consistent
with the graphical evaluations, concomitant exenatide
Figure 1 Mean single-dose plasma concentration-time profiles
for ethinyl estradiol.
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administration did not alter the bioavailability (as mea-
sured by AUC0-∞) of EE or LV, as the 90% confidence
intervals (CI) for the ratios of the least-squares (LS) geo-
metric means were contained within the pre-specified
“no effect” range (0.8 to 1.25). Administration of OC
1 hour before exenatide did not result in a change in
Cmax for either EE or LV, but administration of OC
30 minutes after exenatide resulted in reductions in
Cmax of 46% and 41% for EE and LV, respectively, com-
pared to OC given alone. These reductions in Cmax were
accompanied by median Tmax increases of 4.05 and 3.75
hours for EE and LV, respectively. No differences in
trough concentrations of either EE or LV were observed
when OC was administered 1 hour before exenatide.
Increases in trough concentrations for both EE (24%)
and LV (15%) were observed when OC was adminis-
tered 30 minutes after exenatide.
Multiple-dose pharmacokinetics
Mean plasma concentration time profiles following
repeated daily dosing (Day 22) are presented in Figures 3
(EE) and 4 (LV). Similar to the single-dose PK evalua-
tions, results from the multiple-dose PK assessments
demonstrated that administration of OC 30 minutes after
exenatide reduced Cmax and delayed Tmax for both EE
and LV compared with OC given alone. As with the sin-
gle-dose period, PK differences following repeated daily
dosing were mainly evident in the absorptive phase.
When OC was given 1 hour before exenatide, no changes
in the OC PK profiles were observed.
Between-treatment statistical comparisons for multi-
ple-dose PK parameters are shown in Table 1 (EE) and
Table 2 (LV). As with the single-dose data, regardless of
timing of exenatide administration relative to OC dosing,
no changes in bioavailability (AUC0-τ, ss) of either EE or
LV were observed after concomitant repeated daily
administration of OC and exenatide. Compared to OC
given alone, repeated daily administration of OC 1 hour
before exenatide resulted in a small reduction in EE Cmax
of approximately 15% but did not alter LV Cmax. Reduc-
tions in Cmax were more notable when the OC was admi-
nistered 30 minutes after exenatide. Repeated daily doses
of OC given 30 minutes after exenatide reduced EE and
LV Cmax by 45% and 27%, respectively, compared with
OC given alone. Median Tmax was also delayed by 3
hours and 3.5 hours for EE and LV, respectively, com-
pared with OC alone. As observed in the single-dose
results, increases in trough concentrations for both EE
(20%) and LV (11%) were observed when OC was admi-
nistered 30 minutes after exenatide. No differences in
trough concentrations of EE or LV were observed when
OC was administered 1 hour before exenatide.
Discussion
In this pharmacokinetic drug-interaction study, co-
administration with exenatide did not affect mean plasma
AUC of EE and LV under single- or multiple-dose condi-
tions. Furthermore, no decreases in trough concentra-
tions were observed. Additionally, no substantive changes
in PK profiles were observed when the OC was adminis-
tered 1 hour before exenatide. A small effect was
observed (90% CI; 0.78, 0.93) in Cmax when OC was
administered alone, however, as the lower confidence
bound is close to 0.8, this shift is not likely to be of clini-
cal relevance. Reductions in peak OC concentrations,
accompanied by delayed Tmax, were observed with OC
administered 30 minutes after exenatide. This effect of
exenatide on OC absorption would be expected, due to
its action to slow gastric emptying, and is consistent with
prior drug-drug interaction studies of exenatide with
other orally administered drugs [8-12].
Drug-drug interaction studies with oral contraceptives
are generally conducted to understand the potential for
concomitantly administered drugs to induce or inhibit
cytochrome P450 isoenzyme (CYP) mediated oxidative
metabolism of EE [16]. While EE is metabolised by both
CYP3A-mediated oxidative metabolism and Phase II
metabolism, including glucuronidation and sulfation, the
most clinically relevant metabolic pathway is induction
or inhibition of CYP3A. Drugs that decrease EE bioa-
vailability via CYP3A induction may potentially result in
reduced OC efficacy. The observation that OC AUC
concentrations were unaltered in this study confirmed
that exenatide does not induce CYP3A. However, the
clinical relevance of Cmax reductions seen in the study
(up to 46% for EE and 41% for LV) requires additional
consideration.
Reports of large inter-subject variability in concentra-
tions of OCs, with several-fold differences in serum con-
centrations likely due to inter-individual differences in
first-pass metabolism, have been described in the
Figure 2 Mean single-dose plasma concentration-time profiles
for levonorgestrel.
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literature. Goldzieher et al. [17] have reported that differ-
ences in EE concentrations have been shown to vary
between ethnic groups, as well as across study sites and,
even for a given individual, EE AUCs can vary by almost
a factor of 4. This same study group has also reported
the existence of high intra- and inter-subject variability
in the pharmacokinetics of progestins such as LV [17].
Thus, the magnitude of Cmax reduction observed in the
present study was likely within the inherent PK variability
of the OC components.
The current study did not measure OC pharmacody-
namics (eg, follicle-stimulating hormone or luteinizing
hormone concentrations); therefore, a direct within-study
clinical relationship with the observed Cmax reduction can-
not be derived. Importantly, no break-through bleeding
was reported. Break-through bleeding may be associated
with low concentrations of estrogen-progestin [16,18].
A review of prescription labeling indicates that drug
interactions with OCs are deemed to be clinically impor-
tant, and dosage adjustments are thereby recommended,
only when associated with a significant reduction in OC
AUC. However, there does not appear to be a well-
accepted minimum threshold concentration for pharma-
cological activity. Importantly, in this study OC AUC was
unchanged. Furthermore, trough concentrations did not
decrease in the presence of exenatide suggesting that
sub-therapeutic concentrations were unlikely.
In the absence of conclusive literature on the exposure-
efficacy relationships of OCs, other aspects of OC PK/PD
were considered to help understand the possible clinical
relevance of the Cmax decrease observed in the present
study. In food-effect studies, OC Cmax reductions of up to
40% are commonly observed without changes in AUC.
Despite this potential effect of food on Cmax, OCs are gen-
erally recommended to be taken without regard to food
[19], suggesting that PK changes observed in this study are
not likely to be clinically relevant. In the current study, the
effect of food consumption on the OC PK cannot be
clearly differentiated from the effects of exenatide; how-
ever, these data reflect conditions under which the 2 drugs
are likely to be co-administered, given that exenatide is to
be administered within an hour of meals. Thus, in consid-
eration of indirect evidence from food-effect studies, the
large inherent variability in OC concentrations, and the
Table 1 Ethinyl Estradiol Single- and Multiple-dose Pharmacokinetics: Comparison of Mean Pharmacokinetic
Parameters Across Treatments
Single Dose Multiple Dose
LS Geometric
Mean




Comparison to OC alone:
Ratio (90% CI)
AUC (pg·h/mL) OC alone 718.89 - 761.06 -
1 h before
exenatide
691.69 0.96 (0.91, 1.02) 716.70 0.94 (0.88, 1.01)
0.5 h after
exenatide
692.56 0.96 (0.91, 1.02) 734.01 0.96 (0.90, 1.04)
Cmax (pg/mL) OC alone 72.18 - 102.15 -
1 h before
exenatide
65.49 0.91 (0.83, 0.99) 87.09 0.85 (0.78, 0.93)
0.5 h after
exenatide
38.64 0.54 (0.49, 0.58) 56.32 0.55 (0.50, 0.60)
24-h concentration (pg/
mL)
OC alone 8.27 - 14.64 -
1 h before
exenatide
8.13 0.98 (0.92, 1.05) 15.03 1.03 (0.95, 1.11)
0.5 h after
exenatide
10.25 1.24 (1.16, 1.33) 17.52 1.20 (1.10, 1.30)
Tmax median (range) (h) OC alone - 1.50 (0.50-2.50) - -
1 h before
exenatide
- 1.50 (0.50-2.00) - -
0.5 h after
exenatide
- 6.00 (2.00-6.13) - -
t1/2 geometric mean
(range) (h)
OC alone - 19.5 (13.8-32.1) - -
1 h before
exenatide
- 18.9 (14.0-30.1) - -
0.5 h after
exenatide
- 17.4 (8.78-31.9) - -
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fact that product labeling suggests changes in OC dosage
only in the presence of large changes in OC AUC alone,
we conclude that the PK changes observed in the present
study are not likely to have clinical implications.
Concomitant administration of exenatide and a com-
bination OC to healthy female subjects resulted in a
high incidence of gastrointestinal adverse events. This
study used 4-day dose initiation at 5 μg BID, rather than
4 weeks as recommended for exenatide dosing [20], and
Table 2 Levonorgestrel Single- and Multiple-dose Pharmacokinetics: Comparison of Mean Pharmacokinetic Parameters
Across Treatments
Single Dose Multiple Dose
LS Geometric
Mean




Comparison to OC alone:
Ratio (90% CI)
AUC (pg·h/mL) OC alone 55698.79 - 72974.62 -
1 h before
exenatide
53530.64 0.96 (0.90, 1.03) 72952.67 1.00 (0.92, 1.09)
0.5 h after
exenatide
60591.89 1.09 (1.01, 1.17) 76344.29 1.05 (0.96, 1.14)
Cmax (pg/mL) OC alone 3882.56 - 6598.95 -
1 h before
exenatide
4061.86 1.05 (0.94, 1.16) 6657.22 1.01 (0.92, 1.10)
0.5 h after
exenatide
2284.25 0.59 (0.53, 0.65) 4800.68 0.73 (0.67, 0.79)
24-h concentration (pg/
mL)
OC alone 600.88 - 2136.51 -
1 h before
exenatide
571.47 0.95 (0.89, 1.02) 2173.05 1.02 (0.93, 1.11)
0.5 h after
exenatide
691.10 1.15 (1.07, 1.23) 2367.68 1.11 (1.01, 1.21)
Tmax median (range) (h) OC alone - 1.00 (0.50-2.07) - -
1 h before
exenatide
- 0.92 (0.50-1.50) - -
0.5 h after
exenatide
- 4.75 (3.00-6.02) - -
t1/2 geometric mean
(range) (h)
OC alone - 33.6 (20.0-78.5) - -
1 h before
exenatide
- 32.1 (19.8-55.7) - -
0.5 h after
exenatide
- 32.6 (17.9-72.4) - -
Figure 3 Mean steady-state plasma concentration-time profiles
for ethinyl estradiol.
Figure 4 Mean steady-state plasma concentration-time profiles
for levonorgestrel.
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this may have contributed to the poor tolerability.
Furthermore, cross-study comparisons have suggested
that exenatide administration may result in a higher
incidence of gastrointestinal adverse events in healthy
subjects compared with patients with type 2 diabetes
[8]. More specifically, the high incidence of nausea and
vomiting observed in the present drug-drug interaction
study has not been observed in large clinical trials of
exenatide-treated patients with type 2 diabetes [21-24].
Additionally, although there were no unexpected adverse
events observed in this study, the incidence of skin-
related adverse events among exenatide-treated subjects
(53%) was higher than the incidence observed in pre-
vious clinical studies [21-24].
Conclusions
This study evaluated the potential effect of subcutaneously
administered exenatide (10 μg BID) on the single and mul-
tiple doses pharmacokinetics of a combination OC (EE/
LV). No pharmacokinetic interaction was observed when
the OC was administered an hour prior to exenatide treat-
ment. However, administration of the OC 30 minutes
after exenatide therapy was associated with a reduced
Cmax with a delayed Tmax of EE and LV. The observed
reduction in Cmax is likely of limited importance as co-
administration of exenatide did not cause significant
changes in the overall bioavailability of EE or LV after sin-
gle or multiple doses. For oral medications that are depen-
dent on threshold concentrations for efficacy, such as
contraceptives and antibiotics, patients should be advised
to take those drugs at least 1 hour before exenatide
injection.
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